Share
Blog
Cite
Print
Email
BookmarkScienceDaily (May 25, 2004) — NEW ORLEANS – May 24, 2004 -- Researchers are making promising steps towards the development of a number of vaccines against foodborne disease, according to several studies released today at the 104th General Meeting of the American Society for Microbiology.
See also:
"Vaccines have been proven to be an effective means of prevention for many infectious diseases, but there are no effective vaccines for most common foodborne diseases," says John Gunn of the Ohio State University who presents research on a new vaccine against multiple bacteria. "The development of a single vaccine that provides protection against the most common foodborne pathogens would greatly enhance human health and well-being worldwide."
Gunn and his colleagues have developed a strategy using a live, crippled strain of Salmonella bacteria that do not cause disease and outfit it with "pieces" of other bacterial pathogens to stimulate immunity to multiple pathogens.
"We have already developed a highly attenuated Salmonella typhimurium strain which functions as an effective live, oral vaccine against S. typhimurium," says Gunn.
The researchers modified the vaccine strain so that it also contains a gene from another foodborne pathogen, Listeria monocytogenes. When they administered the modified oral vaccine to mice, it protected them 100 percent against lethal doses of both foodborne bacteria.
Another group of researchers at the meeting today announced they were one step closer toward the development of an edible vaccine against the most virulent forms of the Escherichia coli bacteria, known as shiga toxin-producing E. coli, which include the destructive E. coli O157:H7. These bacteria, because of the shiga toxin they produce, can cause mild to bloody diarrhea and in some cases are responsible for a complication known as hemolytic uremic syndrome, which is characterized by kidney failure, brain damage and sometimes death.
Sharon Wen and her colleagues at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, successfully transferred a modified version of one of the shiga toxin genes into tobacco plants. This plant-derived vaccine was effective in producing antibodies against the toxin when administered to mice.
"Next the immunized mice will be challenged with the toxin or toxin-producing bacteria to determine if the plant vaccine is protective," says Wen. "Once the protective efficacy of these plant-based vaccines is established, the bacterial genes can then be moved into other plants such as bananas or corn for delivery to humans or animals."
